










**Figure 1S.** OHT-treated U87 GBM cells demonstrate a decrease in viable cell number after 24h as determined by calcein-AM conversion. \* $p < 0.05$ .






**Figure 2S.** OHT-treated X1016 GBM PDX cells demonstrate a decrease in viable cell number after 24h as determined by calcein-AM conversion. \* $p < 0.05$ .






**Figure 3S.** OHT-treated JX6 GBM PDX cells demonstrate a decrease in viable cell number after 24h as determined by calcein-AM conversion. \* $p < 0.05$ .



**Figure 4S.** OHT-treated U87 GBM cells demonstrate no increase in caspase 3-like enzymatic activity as determined by DEVD-AMC cleavage. Stuarosporine (STS) was used as a positive control. \* $p < 0.05$ .





**Figure 5S.** OHT-treated X1016 PDX GBM cells demonstrate an increase in caspase 3-like enzymatic activity as determined by DEVD-AMC cleavage. Stuarosporine (STS) was used as a positive control. \* $p < 0.05$ .





**Figure 6S.** OHT-treated JX6 PDX GBM cells demonstrate an increase in caspase 3-like enzymatic activity as determined by DEVD-AMC cleavage. Stuarosporine (STS) was used as a positive control. \* $p < 0.05$ .



JX6 9-1-13



JX6 9-4-13




JX6 9-7-13




**Figure 7S.** BAF attenuates OHT-induced caspase 3-like enzymatic activity that results in a partial but statistically significant protection from OHT-induced reduction in cell viability. \* $p < 0.05$ .

# U87 11-18-13




U87 UT 11-18-13  
Gated Events: 10,000

Et+ 9.25%




U87 TMX 3 11-18-13  
Gated Events: 10,000

Et+ 8.34%




U87 TMX 6 11-18-13  
Gated Events: 10,000

Et+ 9.02%



U87 TMX 9 11-18-13  
Gated Events: 10,000

Et+ 19.07%




U87 TMX 12 11-18-13  
Gated Events: 10,000

Et+ 29.3%

**Figure 8S.** OHT-treated (TMX) U87 GBM cells exhibit an increase in dead (Et+) cells after 24h as determined by calcein/ethidium homodimer staining and flow cytometric analysis.




# U87 11-22-13




Et+ 15.58%

U87 UT 11-22-13  
Gated Events: 10,000




Et+ 19.41%

U87 TMX 3 11-22-13  
Gated Events: 10,000




Et+ 48.76%

U87 TMX 6 11-22-13  
Gated Events: 10,000



Et+ 53.43%

U87 TMX 9 11-22-13  
Gated Events: 10,000




Et+ 65%


U87 TMX 12 11-22-13  
Gated Events: 10,000

**Figure 9S.** OHT-treated (TMX) U87 GBM cells exhibit an increase in dead (Et+) cells after 24h as determined by calcein/ethidium homodimer staining and flow cytometric analysis.


# U87 11-27-13




U87 UT 11-27-13  
Gated Events: 10,000  
**Et+ 4.06%**




U87 TMX 3 11-27-13  
Gated Events: 10,000  
**Et+ 6.74%**



U87 TMX 6 11-27-13  
Gated Events: 10,000  
**Et+ 10.36%**




U87 TMX 9 11-27-13  
Gated Events: 10,000  
**Et+ 36.53%**




U87 TMX 12 11-27-13  
Gated Events: 10,000  
**Et+ 43.63%**


**Figure 10S.** OHT-treated (TMX) U87 GBM cells exhibit an increase in dead (Et+) cells after 24h as determined by calcein/ethidium homodimer staining and flow cytometric analysis.




**Figure 11S.** OHT-treated U87 GBM cells exhibit an increase in LC3-II accumulation after 24h as demonstrated by western blot. Chloroquine (CQ) was used as a positive control.




**Figure 12S.** OHT-treated X1016 PDX GBM cells exhibit an increase in LC3-II accumulation after 24h as demonstrated by western blot. Chloroquine (CQ) was used as a positive control.



**Figure 13S.** OHT-treated JX6 PDX GBM cells exhibit an increase in LC3-II accumulation after 24h as demonstrated by western blot. Chloroquine (CQ) was used as a positive control.



**Figure 14S.** OHT+Baf A1-treated U87 GBM cells exhibit an increase in LC3-II accumulation relative to OHT or Baf A1 treatment alone as demonstrated by western blot.



**Figure 15S.** OHT+Baf A1-treated X1016 PDX GBM cells exhibit an increase in LC3-II accumulation relative to OHT or Baf A1 treatment alone as demonstrated by western blot.

JX6 9-8-13

1.0      3.07      1.95      4.58

14 kD

37 kD

Relative  
Expression

LC3-II

GAPDH

UT      Baf A1      OHT      Baf A1  
100nM      12 $\mu$ M      +  
OHT

JX6 3-11-14

1.0      11.90      9.24      17.31

14 kD

37 kD

Relative  
Expression

LC3-II

GAPDH




UT      Baf A1      OHT      Baf A1  
100nM      12 $\mu$ M      +  
OHT

**Figure 16S.** OHT+Baf A1-treated JX6 PDX GBM cells exhibit an increase in LC3-II accumulation relative to OHT or Baf A1 treatment alone as demonstrated by western blot.



U87 8-20-13

NT siRNA                      *atg5* siRNA






OHT 12µM


-      -      +      +

**Figure 17S.** Knockdown of *atg5* results in a reduction in OHT-induced LC3-II accumulation and a significant protection from OHT-induced death. \* $p < 0.05$ .


# U87 *atg5* KD 9-29-15



**Figure 18S.** Knockdown of *atg5* results in a reduction in OHT-induced LC3-II accumulation and a significant protection from OHT-induced death. \* $p < 0.05$ .






**Figure 19S.** OHT-treated U87 GBM cells exhibit a reduction in EGFR protein after 24h as demonstrated by western blot.



**Figure 20S.** OHT-treated U87vIII GBM cells exhibit no reduction in EGFR protein after 24h as demonstrated by western blot.


**Figure 21S.** OHT-treated U87vIII GBM cells exhibit a decrease in OHT-induced reduction in cell viability after 24h. \*p<0.05.




\*

\*

\*




**Figure 22S.** OHT-treated U87 GBM cells exhibit a time-dependent decrease in EGFR protein in the presence of the protein synthesis inhibitor cycloheximide (CHX) as demonstrated by western blot.






**Figure 23S.** OHT-treated JX6 PDX GBM cells exhibit a decrease in EGFR protein after 24h as demonstrated by western blot.

JX6 4-17-14




**Figure 24S.** OHT-treated JX6 PDX GBM cells exhibit a decrease in EGFR protein after 24h as demonstrated by immunocytochemistry.








**Figure 25S.** OHT-treated U87 GBM cells exhibit a decrease in p-AKT (S473) after 24h as demonstrated by western blot.



**Figure 26S.** TFP and Ro31 recapitulate OHT's effects on LC3-II and EGFR after 24h as demonstrated by western blot.



**Figure 27S.** TFP, but not Ro31, recapitulates OHT's effects on AKT activation in U87 GBM cells after 24h as demonstrated by western blot.